CL2012003350A1 - Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. - Google Patents
Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares.Info
- Publication number
- CL2012003350A1 CL2012003350A1 CL2012003350A CL2012003350A CL2012003350A1 CL 2012003350 A1 CL2012003350 A1 CL 2012003350A1 CL 2012003350 A CL2012003350 A CL 2012003350A CL 2012003350 A CL2012003350 A CL 2012003350A CL 2012003350 A1 CL2012003350 A1 CL 2012003350A1
- Authority
- CL
- Chile
- Prior art keywords
- drug
- risperidone
- lactic
- copolymer
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382154.2A EP2394664B1 (en) | 2010-05-31 | 2010-05-31 | Antipsychotic injectable depot composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012003350A1 true CL2012003350A1 (es) | 2013-10-18 |
Family
ID=43301889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012003350A CL2012003350A1 (es) | 2010-05-31 | 2012-11-29 | Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10085936B2 (es) |
| EP (2) | EP2394664B1 (es) |
| JP (1) | JP5882993B2 (es) |
| KR (1) | KR101784330B1 (es) |
| CN (1) | CN103002917B (es) |
| AP (1) | AP3524A (es) |
| AU (1) | AU2011260318B2 (es) |
| BR (1) | BR112012030686B1 (es) |
| CA (1) | CA2800111C (es) |
| CL (1) | CL2012003350A1 (es) |
| CY (2) | CY1117969T1 (es) |
| DK (2) | DK2394664T3 (es) |
| EA (1) | EA024155B1 (es) |
| ES (2) | ES2589106T3 (es) |
| HR (2) | HRP20161049T1 (es) |
| HU (2) | HUE029895T2 (es) |
| IL (1) | IL223129A (es) |
| LT (2) | LT2394664T (es) |
| MA (1) | MA34296B1 (es) |
| ME (1) | ME02501B (es) |
| MX (1) | MX338373B (es) |
| MY (1) | MY161930A (es) |
| NZ (1) | NZ604342A (es) |
| PL (2) | PL2394664T3 (es) |
| PT (2) | PT2394664T (es) |
| RS (1) | RS55190B1 (es) |
| SG (1) | SG185775A1 (es) |
| SI (2) | SI2394664T1 (es) |
| SM (2) | SMT201600320B (es) |
| UA (1) | UA108885C2 (es) |
| WO (1) | WO2011151355A1 (es) |
| ZA (1) | ZA201209346B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| JP2010531807A (ja) | 2007-05-25 | 2010-09-30 | トルマー セラピューティクス， インコーポレイテッド | リスペリドン化合物の徐放送達製剤 |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) * | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| LT2394663T (lt) | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| PT2529756T (pt) * | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| WO2016199170A2 (en) * | 2015-06-10 | 2016-12-15 | Cipla Limited | Paliperidone palmitate particles and compositions thereof |
| US10646443B2 (en) | 2017-03-20 | 2020-05-12 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| CN110420212A (zh) * | 2019-08-19 | 2019-11-08 | 韩自勤 | 一种用于治疗精神分裂症组合物及其制备方法 |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| SK282231B6 (sk) | 1993-11-19 | 2001-12-03 | Janssen Pharmaceutica N. V. | Farmaceutický prostriedok na liečenie psychotických porúch |
| DK0959873T3 (da) | 1996-12-20 | 2006-07-03 | Alza Corp | Gelsammensætning og fremgangsmåder |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6331317B1 (en) * | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
| WO2001051024A2 (de) * | 2000-01-11 | 2001-07-19 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösemittel |
| US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
| EP2030611A1 (en) * | 2002-07-31 | 2009-03-04 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| EP1660039B1 (en) * | 2003-07-18 | 2016-09-28 | Oakwood Laboratories L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
| PT2115029E (pt) | 2007-02-15 | 2015-10-26 | Tolmar Therapeutics Inc | Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros |
| CA2686137C (en) * | 2007-05-18 | 2021-01-12 | Durect Corporation | Improved depot formulations |
| JP2010531807A (ja) | 2007-05-25 | 2010-09-30 | トルマー セラピューティクス， インコーポレイテッド | リスペリドン化合物の徐放送達製剤 |
| AR070033A1 (es) * | 2007-11-06 | 2010-03-10 | Panacea Biotec Ltd | Composiciones inyectables, sus procesos y usos |
| CN102119022B (zh) * | 2008-08-12 | 2015-09-09 | 诺华股份有限公司 | 药物组合物 |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| LT2394663T (lt) | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| PT2529756T (pt) | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
-
2010
- 2010-05-31 ES ES10382154.2T patent/ES2589106T3/es active Active
- 2010-05-31 LT LTEP10382154.2T patent/LT2394664T/lt unknown
- 2010-05-31 HU HUE10382154A patent/HUE029895T2/en unknown
- 2010-05-31 PL PL10382154.2T patent/PL2394664T3/pl unknown
- 2010-05-31 EP EP10382154.2A patent/EP2394664B1/en active Active
- 2010-05-31 PT PT103821542T patent/PT2394664T/pt unknown
- 2010-05-31 SI SI201031270A patent/SI2394664T1/sl unknown
- 2010-05-31 DK DK10382154.2T patent/DK2394664T3/en active
-
2011
- 2011-05-31 LT LTEP11725383.1T patent/LT2575890T/lt unknown
- 2011-05-31 MY MYPI2012701044A patent/MY161930A/en unknown
- 2011-05-31 HU HUE11725383A patent/HUE029056T2/en unknown
- 2011-05-31 ME MEP-2016-178A patent/ME02501B/me unknown
- 2011-05-31 SG SG2012087136A patent/SG185775A1/en unknown
- 2011-05-31 AP AP2012006626A patent/AP3524A/xx active
- 2011-05-31 RS RS20160730A patent/RS55190B1/sr unknown
- 2011-05-31 KR KR1020127033021A patent/KR101784330B1/ko active IP Right Grant
- 2011-05-31 BR BR112012030686-3A patent/BR112012030686B1/pt active IP Right Grant
- 2011-05-31 AU AU2011260318A patent/AU2011260318B2/en active Active
- 2011-05-31 MX MX2012013937A patent/MX338373B/es active IP Right Grant
- 2011-05-31 DK DK11725383.1T patent/DK2575890T3/en active
- 2011-05-31 MA MA35428A patent/MA34296B1/fr unknown
- 2011-05-31 PL PL11725383.1T patent/PL2575890T3/pl unknown
- 2011-05-31 ES ES11725383.1T patent/ES2592527T3/es active Active
- 2011-05-31 JP JP2013512879A patent/JP5882993B2/ja active Active
- 2011-05-31 EA EA201201569A patent/EA024155B1/ru unknown
- 2011-05-31 EP EP11725383.1A patent/EP2575890B1/en active Active
- 2011-05-31 CA CA2800111A patent/CA2800111C/en active Active
- 2011-05-31 WO PCT/EP2011/059000 patent/WO2011151355A1/en active Application Filing
- 2011-05-31 PT PT117253831T patent/PT2575890T/pt unknown
- 2011-05-31 SI SI201130939A patent/SI2575890T1/sl unknown
- 2011-05-31 UA UAA201214486A patent/UA108885C2/ru unknown
- 2011-05-31 CN CN201180026475.2A patent/CN103002917B/zh active Active
- 2011-05-31 NZ NZ604342A patent/NZ604342A/en unknown
-
2012
- 2012-11-19 IL IL223129A patent/IL223129A/en active IP Right Grant
- 2012-11-29 CL CL2012003350A patent/CL2012003350A1/es unknown
- 2012-11-30 US US13/690,647 patent/US10085936B2/en active Active
- 2012-12-10 ZA ZA2012/09346A patent/ZA201209346B/en unknown
-
2016
- 2016-08-19 HR HRP20161049TT patent/HRP20161049T1/hr unknown
- 2016-08-29 HR HRP20161100TT patent/HRP20161100T1/hr unknown
- 2016-08-31 CY CY20161100857T patent/CY1117969T1/el unknown
- 2016-08-31 CY CY20161100858T patent/CY1117964T1/el unknown
- 2016-09-15 SM SM201600320T patent/SMT201600320B/it unknown
- 2016-09-15 SM SM201600321T patent/SMT201600321B/it unknown
-
2018
- 2018-04-04 US US15/944,894 patent/US10182982B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003350A1 (es) | Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. | |
| CL2013001942A1 (es) | Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. | |
| BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
| ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| CL2014003215A1 (es) | Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion | |
| WO2012019426A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| WO2011019326A3 (en) | Solubility and stability enchancing pharmaceutical formulation | |
| WO2012019430A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| EP3308785A3 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
| WO2015120237A3 (en) | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
| BR112012018695A2 (pt) | compostos pirazol como antagonistas crth2 | |
| ES2408343R1 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
| BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
| WO2014101295A3 (zh) | 一种詹纳斯激酶（jaks）抑制活性的异恶唑衍生物 | |
| WO2011126839A3 (en) | Compositions and methods for improved retention of a pharmaceutical composition at a local administration site | |
| BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| EP2549874A4 (en) | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | |
| WO2014164648A3 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |